Scientific Directorate, Fondazione IRCCS - Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy.
Mol Oncol. 2010 Feb;4(1):19-37. doi: 10.1016/j.molonc.2009.10.003. Epub 2009 Oct 28.
This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and provide the opportunity to develop new therapies also for more common cancer types. We discuss the activation of the downstream RTK effectors as further targets for therapies in colorectal cancer. Finally, we highlight how a novel multidimensional approach which adds an in silico dimension to the in vitro and in vivo approach, can predict clinical results.
这篇综述分析了几种肿瘤的靶向治疗现状，从伊马替尼治疗慢性髓性白血病（CML）的典范范例开始。我们讨论了罕见肿瘤如何成为受体酪氨酸激酶（RTK）激活各种机制的模型，并为更常见的癌症类型提供了开发新疗法的机会。我们讨论了结直肠癌中 RTK 效应器的激活作为治疗的进一步靶点。最后，我们强调了如何通过将体外和体内方法与计算维度相结合的新多维方法来预测临床结果。
